This article covers emerging musculoskeletal and regenerative-medicine research. It reflects what may be coming in the field, not the treatments ADX or its network physicians currently provide.
Why It Matters
A torn rotator cuff is one of the most common shoulder injuries, and it can make everyday things – reaching a shelf, getting dressed, sleeping through the night – painful or impossible. Even after surgery, these tendons often heal slowly or incompletely because the worn, injured tissue has a hard time rebuilding itself. Researchers are testing a new idea: an injection that delivers living repair cells, packed inside a supportive gel, right to the damaged spot to help the tendon regrow stronger. A recent study shows this approach working in the lab, an early but encouraging step toward better treatment for shoulder injuries.
What the Research Says
In a 2026 study in the Journal of Orthopaedic Research, Choi and colleagues tested an injectable treatment that combines two ingredients: clusters of adipose-derived stem cells (repair cells taken from fat tissue) and a collagen hydrogel, a soft, natural scaffold that holds the cells in place. The team first grew the stem cells into tiny three-dimensional spheres, or spheroids, a format that helps the cells survive and stay active longer than loose, single cells. They then mixed those spheroids into the collagen gel so the whole package could be injected directly into an injured tendon.
To see whether it worked, the researchers used an animal model of rotator cuff injury and compared four groups: no treatment, stem cell spheroids alone, collagen gel alone, and the combined spheroid-plus-collagen injection. They measured healing in two ways – by examining the tendon tissue under the microscope with several specialized stains, and by mechanically testing how strong the repaired tendon had become.
The combination treatment came out clearly ahead. Tendons that received the spheroid-and-collagen injection showed better-organized healing tissue and greater mechanical strength than the tendons in the other groups, suggesting the two ingredients work better together than either does alone. Just as important for safety, the study found no signs of toxicity or tumor formation, and the delivered cells stayed put at the injection site for up to 16 weeks, doing their work where they were needed rather than drifting elsewhere in the body.
It is important to read these results for what they are: a promising preclinical study, not a treatment available in clinic today. The work was done in an animal model, and human trials would be needed to confirm that it is safe and effective in people. Still, the findings matter because they point toward a future where a single, well-targeted injection could help the body rebuild its own damaged tendon tissue – a meaningful direction for anyone working at the leading edge of musculoskeletal care.
Source: Journal of Orthopaedic Research, Choi et al., 2026
Research compiled by ADX AI Agent, reviewed by Sean Gallivan